Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | - USD | 100.0% |
| 2022 | -31.28 Thousand USD | 0.13% |
| 2021 | -31.32 Thousand USD | 0.3% |
| 2020 | -31.42 Thousand USD | -0.4% |
| 2019 | -31.29 Thousand USD | 75.32% |
| 2018 | -126.84 Thousand USD | 29.13% |
| 2017 | -178.97 Thousand USD | 0.0% |
| 2009 | 544.51 Thousand USD | 486.63% |
| 2008 | -140.83 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 FY | -31.28 Thousand USD | 0.13% |
| 2022 Q2 | -7823.00 USD | -0.01% |
| 2022 Q3 | -7824.00 USD | -0.01% |
| 2022 Q4 | -7821.00 USD | 0.04% |
| 2022 Q1 | -7822.00 USD | 0.51% |
| 2021 Q2 | -7823.00 USD | -0.01% |
| 2021 FY | -31.32 Thousand USD | 0.3% |
| 2021 Q4 | -7862.00 USD | -0.5% |
| 2021 Q3 | -7823.00 USD | 0.0% |
| 2021 Q1 | -7822.00 USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | -31.42 Thousand USD | -0.4% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | -31.29 Thousand USD | 75.32% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | -126.84 Thousand USD | 29.13% |
| 2017 FY | -178.97 Thousand USD | 0.0% |
| 2010 Q1 | -194.08 Thousand USD | -35744.07% |
| 2010 Q2 | -233.6 Thousand USD | -20.36% |
| 2009 FY | 544.51 Thousand USD | 486.63% |
| 2009 Q4 | 544.52 USD | 0.0% |
| 2009 Q2 | 21.29 Thousand USD | -85.01% |
| 2009 Q1 | 142.06 Thousand USD | 0.0% |
| 2008 FY | -140.83 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 100.0% |
| Aridis Pharmaceuticals, Inc. | - USD | NaN% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 100.0% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 100.0% |
| Better Therapeutics, Inc. | -2.72 Million USD | 100.0% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 100.0% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 100.0% |
| Gene Biotherapeutics, Inc. | - USD | NaN% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.0% |
| Eloxx Pharmaceuticals, Inc. | - USD | NaN% |
| Evelo Biosciences, Inc. | - USD | NaN% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 100.0% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 100.0% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 100.0% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 100.0% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 100.0% |
| Molecular Templates, Inc. | 50.39 Million USD | 100.0% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 100.0% |
| NexImmune, Inc. | -1.02 Million USD | 100.0% |
| Orgenesis Inc. | -5.72 Million USD | 100.0% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 100.0% |
| PaxMedica, Inc. Common Stock | - USD | NaN% |
| Scopus BioPharma Inc. | - USD | NaN% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.0% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 100.0% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 100.0% |
| Trevena, Inc. | 1.45 Million USD | 100.0% |
| Vaxxinity, Inc. | -2.23 Million USD | 100.0% |
| Vaccinex, Inc. | -16 Million USD | 100.0% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 100.0% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 100.0% |